NEW YORK — The biopharmaceutical maker Bristol-Myers Squibb Co. has reached an agreement to acquire clinical-stage biopharmaceutical company Inhibitex, Inc.
Bristol-Myers (NYSE: BMY), based in New York City, will pay approximately $2.5 billion for Inhibitex (NASDAQ: INHX), which is based in Alpharetta, Ga., outside of Atlanta. Bristol-Myers plans to purchase Inhibitex stock for $26 per share in cash. It will finance the deal using existing cash resources.
The acquisition gives Bristol-Myers, which employs about 420 people at a site in DeWitt, an antiviral drug Inhibitex is developing to treat the hepatitis C virus. That drug, INX-189, is in Phase II development.
(Sponsored)
Close the Skills Gap: Build Your Workforce with MACNY Registered Apprenticeship Program
In today’s competitive labor market, finding qualified candidates through traditional hiring methods has never been more challenging. As industries evolve and workforce demands shift, employers are facing a growing skills
Asset Acquisition Strategies: Choosing Between Financing, Leasing or Buying
When acquiring business equipment or machinery, how you choose to pay can significantly impact your cash flow, tax strategy and long-term financial position. The three primary optionsare financing, leasing and
“The acquisition of Inhibitex builds on Bristol-Myers Squibb’s long history of discovering, developing, and delivering innovative new medicines in virology and enriches our portfolio of investigational medicines for hepatitis C,” Bristol-Myers CEO Lamberto Andreotti said in a news release.
